* A corporate client of Hybridan LLP
** Arranged by type of listing and date of announcement
*** Alphabetically arranged
**** Potential means Intention to Float (ITF) has been announced, or it is a rumour
Dish of the day
What’s baking in the oven ?
CAP-XX 0.27p £8.2m (CPX.L)
The designer and manufacturer of thin, prismatic supercapacitors and energy management systems announces an unaudited trading update in respect of the financial year ended 30 June 2024. Revenue is expected to be A$4.6m up 26.7% versus the prior financial year. The R&D tax credit of approximately A$1.25m is estimated to be received in November 2024. Year-end cash reserves were A$2.0m and the company is debt free. The Company reports they are making strong progress with their global distribution network and the supercapacitor market is currently experiencing significant growth. The Company's audited results for FY2024 are expected to be released on 29 October 2024.
The global provider of high-precision components, offering comprehensive services from mould design, automation and production to assembly and printing, serving the life sciences, aerospace, optics and tech sectors, provide a trading update this morning. The Group's trading performance year to date is in line with management's expectations. The US manufacturing rationalisation and improvement programme is on track. By focusing on cash management and leveraging stronger trading, the Company has further improved their net debt to EBITDA ratio. Expectations for the FY25 full year and FY26 remain unchanged with margin expansion anticipated to continue.
EDX Medical 11.25p £40.8m (AQSE: EDX)
The developer of innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases announces today the appointment of Eric Vick as Chief Commercial Officer. The appointment follows the successful completion of several key commercial agreements which enable the Company to develop and market a range of innovative diagnostic products and services in the UK and key European countries. Eric has worked in the life sciences sector for more than 25 years, building and leading commercial business units for companies from start-ups to global leaders including GSK, Novartis, ViroPharma, Bio Products Laboratory, Ethypharm and Rosemont Pharma.
Fusion Antibodies 3.15p £3m (FAB.L)
The specialist in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications announces its final results for the year ended 31 March 2024. Audited revenues for FY24 were £1.14m (FY23: £2.90m). There was an increase in sales pipeline opportunities during the second half of FY24, with an orderbook at 31 March 2024 of £0.75m, representing 65 per cent of total FY24 audited revenues. The cash position as at 31 March 2024 of £1.2m (31 March 2023: £0.2m).
The developer of solid-state battery technology announces that safety tests undertaken by independent expert assessors have demonstrated the superior safety of Goliath solid state cell battery prototypes relative to lithium-ion equivalent batteries. University College London carried out the nail penetration test, a standard battery safety assessment, on Ilika's Goliath P1 prototype cells. This destructive test creates an internal electrical short-circuit inside a cell by piercing the cell with a metal nail. The test simulates a catastrophic incident that would typically cause energy-dense lithium-ion cells with lithium nickel manganese cobalt oxide cathode chemistry, to dangerously swell, rupture, explode, and catch fire in a process known as thermal runaway, often leading to temperatures above 600°C. The Company believes these test results contribute to a growing body of evidence demonstrating Goliath's superior safety performance.
The data science and machine learning solutions company and its subsidiaries announced its results for the year ended 31 March 2024. The Company has reduced its adjusted EBITDA loss of £0.6m from £2m in the previous year. The FCA has recognised Insig AI as a key contributor in its anti-greenwashing technology initiative. The CEO, Richard Bernstein, believes they have visibility of regulatory tailwinds that should represent the compelling event in the nascent market of non-financial corporate disclosures.
Kodal Minerals 0.53p £108m (KOD.L)
The mineral exploration and development company provided an update on the progress of construction of the Dense Media Separation (DMS) processing plant and mining at the Ngoualana open pit mine at its flagship fully funded Bougouni Lithium Project in Southern Mali. The DMS and Ngoualana open pit development continues to advance with the open pit mining currently ahead of schedule. Wide, high-grade extensions returned at the Boumou Prospect include 7m at 1.16% Li2O from 147m and 13m at 1.07% Li2O.
Mkango Resources 6.5p £18.1m (MKA.L)
The mineral exploration and development company announces that it has completed a private placement to raise gross proceeds of £1,250,000 at a price per Subscription Share of 5 pence. The Company intends to use the net proceeds of the Subscription to acquire additional equipment for the 2025 commercial development of rare earth magnet recycling operations at Tyseley Energy Park in Birmingham, UK and at Pforzheim, Germany, by HyProMag Limited and HyProMag GmbH, in addition to working capital.
Smarttech247 10p £11.4m (S247.L)
The provider of AI-enhanced cybersecurity services providing automated managed detection and response for a portfolio of international clients announces a trading update for the year to 31 July 2024. The company anticipates that both EBITDA and operating profit will be below market guidance, but the Company will remain profitable after the usual adjustments for non-trading items. Going forward, the Company believes they are well-positioned and well-funded for growth in an exciting sector and with a customer base that clearly values the services that the Company is able to provide.
Xeros Technology Group 0.75p £3.9m (XSG.L)
The creator of technologies that reduce the impact of clothing on the planet announced a trading update and a filtration licence agreement with Donlim Group. The Board is confident that the market for microfibre filtration in washing machines remains significant in the medium term and that the licensing agreements it has in place, including the one with Donlim announced today, leave the Group well placed to generate significant revenues from this developing market. The impact of the delays in the filtration legislation in France is to reduce the Group's revenue expectations for FY24 and FY25 to £0.5m and £3.8m respectively, and adjusted EBITDA loss to £4.2m for FY24 and £1.0m for FY25. The Group anticipates cash balances at 31 December 2024 of £2.9m. Cash at 30 August 2024 was £4.0m, which the Board still expects to be sufficient to finance operations through to month on month cashflow break-even, during the latter part of 2025.
This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document is sent to you as market commentary only. As market commentary this document does not constitute any of (i) investment research and financial analysis or other forms of general recommendation relating to transactions in financial instruments for the purposes of the UK retained version of section B of annex I to Directive 2014/65/EU ("MIFID II Directive"); or (ii) investment research as defined in the UK retained version of article 36(1) of Commission Delegated Regulation 2017/565/EU made pursuant to the MIFID II Directive; or (iii) non-independent research (as such term is defined in the Financial Conduct Authority's Conduct of Business Sourcebook).
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.